<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-5362-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROST
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        55.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rosuvastatin Tablets belongs to a group of medicines called statins. You have been prescribed Rosuvastatin Tablets because:</p><p>&middot;&nbsp; You have a high cholesterol level. This means you are at risk from a heart attack or stroke.</p><p>You have been advised to take a statin, because changing your diet and taking more exercise&nbsp; were&nbsp; not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering&nbsp; diet and exercise while you are taking Rosuvastatin Tablets.</p><p>Or</p><p>&middot;&nbsp; You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to build up of fatty deposits in your arteries.</p><p>Why is it important to keep taking Rosuvastatin Tablets?</p><p>Rosuvastatin Tablets is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><p>&middot;&nbsp; Rosuvastatin Tablets can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</p><p>&middot;&nbsp; It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can&nbsp; reduce your risk of having a heart attack, a stroke or related health problems.</p><p>You need to <strong>keep taking Rosuvastatin Tablets</strong>, even if it has got your cholesterol to the right level, because <strong>it prevents your cholesterol levels from creeping up again </strong>and causing build up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Rosuvastatin Tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have ever had an allergic reaction to Rosuvastatin Tablets</strong>, or to any of its ingredients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are pregnant </strong>or breast-feeding. If you become pregnant while&nbsp; taking Rosuvastatin&nbsp; Tablets <strong>stop taking it immediately and tell your doctor</strong>. Women should avoid becoming pregnant while taking Rosuvastatin Tablets by using suitable contraception.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have severe kidney problems</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have repeated or unexplained muscle aches or pains</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take a drug called ciclosporin </strong>(used, for example, after organ transplants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, do not take Rosuvastatin Tablets 40 mg (the highest dose):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have moderate kidney problems </strong>(if in doubt, please ask your doctor).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If your thyroid gland </strong>is not working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have had any repeated or unexplained muscle aches or pains</strong>, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol lowering medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you regularly drink large amounts of alcohol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are of Asian origin </strong>(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take other medicines called fibrates </strong>to lower your cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor</strong>. <strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Rosuvastatin Tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have problems with your liver</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have had repeated or unexplained muscle aches or pains</strong>, a personal or&nbsp; family history of muscle problems, or a previous history of muscle problems when taking other cholesterol lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you regularly drink large amounts of alcohol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If your thyroid gland </strong>is not working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take other medicines called fibrates </strong>to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take medicines used to treat the HIV infection </strong>e.g. ritonavir with Lopinavir and/or atazanavir, please see Other medicines and Rosuvastatin Tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take antibiotics containing fusidic acid</strong>, please see Other medicines and Rosuvastatin Tablets.</p><p>Children and adolescents</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If the patient is under 10 years old: </strong>Rosuvastatin Tablets should not be given to children younger than 10 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If the patient is below 18 years of age</strong>: The Rosuvastatin Tablets 20 mg tablet is not suitable for use in children and adolescents below 18 years of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are over 70 </strong>(as your doctor needs to choose the right start dose of Rosuvastatin Tablets to suit you)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe respiratory failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are of Asian origin </strong>&ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of Rosuvastatin Tablets to suit you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above applies to you (or if you are not sure):</p><p>Do not take Rosuvastatin Tablets 40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of Rosuvastatin Tablets.</p><p>In a small number of people, statins can affect the liver. This is identified by a simple test&nbsp; which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually&nbsp; carry out this blood test (liver function test) before and during treatment with Rosuvastatin Tablets. While you are on this medicine your doctor will monitor you closely if you have diabetes or&nbsp; are at risk of developing diabetes. You are likely to be at risk of developing diabetes if&nbsp; you&nbsp; have high &nbsp;levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>Other medicines and Rosuvastatin Tablets</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines</p><p>Tell your doctor if you are taking any of the following: ciclosporin (used for example, after organ transplants), warfarin or clopidogrel (or any other drug used for thinning the blood), fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe), indigestion remedies (used to neutralise acid in your stomach), erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see Warnings and precautions), an oral contraceptive (the pill), hormone replacement therapy or ritonavir with lopinavir and/or atazanavir (used to treat the HIV infection &ndash; please see Warnings and precautions). The effects of these medicines could be changed by Rosuvastatin Tablets or they could change the effects of Rosuvastatin Tablets.</p><p>Pregnancy and breast-feeding</p><p><strong>Do not take Rosuvastatin Tablets </strong>if you are pregnant or breast-feeding. If you become pregnant while taking Rosuvastatin Tablets <strong>stop taking it immediately </strong>and tell your doctor. Women should avoid becoming pregnant while taking Rosuvastatin Tablets by using suitable contraception.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>Most people can drive a car and operate machinery while using Rosuvastatin Tablets &ndash; it will not affect their ability. However, some people feel dizzy during treatment with Rosuvastatin Tablets. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p>Rosuvastatin Tablets contains lactose.</p><p>If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk sugar), contact your doctor before taking Rosuvastatin Tablets.</p><p>For a full list of ingredients please see Further information.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Usual doses in adults</p><p><strong>If you are taking Rosuvastatin Tablets for high cholesterol:</strong></p><p><strong>Starting dose</strong></p><p>Your treatment with Rosuvastatin Tablets must start with the <strong>10 mg or the 20 mg dose</strong>, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your cholesterol level.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The level of risk you have of experiencing a heart attack or stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of Rosuvastatin Tablets will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are of <strong>Asian origin </strong>(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are <strong>over 70 years </strong>of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have moderate kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are at risk of muscle aches and pains (myopathy).</p><p>Increasing the dose and maximum daily dose</p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of Rosuvastatin Tablets that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, and then 20 mg if necessary. If you started on 10 mg,&nbsp; your doctor may decide&nbsp; to double this to 20 mg necessary. There will be a gap of four weeks between every dose adjustment. The maximum daily dose of Rosuvastatin Tablets is 20 mg. It is only for patients with high&nbsp; cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p>If you are taking Rosuvastatin Tablets to reduce your risk of having a heart attack, stroke or related health problems:</p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p>Use in children and adolescents aged 10-17 years</p><p>The usual start dose is 10 mg. Your doctor may increase your dose to find the right amount of Rosuvastatin Tablets for you. The maximum daily dose of Rosuvastatin Tablets is 20 mg. Take your dose once a day. Rosuvastatin Tablets <strong>20 mg </strong>tablet should <strong>not </strong>be used by children.</p><p>Taking your tablets</p><p>Swallow each tablet whole with a drink of water.</p><p><strong>Take Rosuvastatin Tablets once daily</strong>. You can take it at any time of the day with or without food. Try to take your tablet at the same time every day to help you to remember it.</p><p>Regular cholesterol checks</p><p>It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of Rosuvastatin Tablets that is right for you.</p><p>If you take more Rosuvastatin Tablets than you should</p><p>Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking Rosuvastatin Tablets.</p><p>If you forget to take Rosuvastatin Tablets</p><p>Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to&nbsp; make up for a forgotten dose.</p><p>If you stop taking Rosuvastatin Tablets</p><p>Talk to your doctor if you want to stop taking Rosuvastatin Tablets. Your cholesterol levels might increase again if you stop taking Rosuvastatin Tablets.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p><strong>Stop taking Rosuvastatin Tablets and seek medical help immediately </strong>if you have any of the following allergic reactions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itching of the skin (with raised lumps).</p><p><strong>Also, stop taking Rosuvastatin Tablets and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than you might expect.</p><p>Muscle symptoms are more common in children and adolescents than in adults.&nbsp; As &nbsp;with&nbsp; other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as <em>rhabdomyolysis</em>.</p><p>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Rosuvastatin Tablets&nbsp; tablets (only Rosuvastatin Tablets 40&nbsp; mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching or other skin reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Rosuvastatin Tablets&nbsp; (only Rosuvastatin Tablets&nbsp; 10&nbsp; mg and 20 mg).</p><p>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty&nbsp; in swallowing and breathing, a severe itching of the skin (with raised lumps). <strong>If you think you&nbsp; are having an allergic reaction, then stop taking Rosuvastatin Tablets </strong>and seek medical help immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle damage in adults &ndash; as a precaution, <strong>stop taking Rosuvastatin Tablets and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than expected</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe stomach pain (inflamed pancreas)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in liver enzymes in the blood</p><p>Very rare possible side effects (these may affect less than 1 in 10,000 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the skin and eyes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis (an inflamed liver)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Traces of blood in your urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the nerves of your legs and arms (such as numbness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Memory loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in men (gynaecomastia)</p><p>Side effects of unknown frequency may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea (loose stools)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (swelling)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disturbances, including insomnia and nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual difficulties</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems, including persistent cough and/or shortness of breath or fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendon injury</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness that is constant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Rosuvastatin Tablets contains <u>Rosuvastatin Tablets 10 mg:</u></strong></p><p>The active substance is Rosuvastatin Calcium.</p><p>Each film coated tablet contains Rosuvastatin calcium Ph. Eur. equivalent to 10 mg of Rosuvastatin.</p><p>The other ingredients are: Lactose Monohydrate, Cellulose, Microcrystalline, Crospovidone, Hydroxypropyl Cellulose, Sodium Hydrogen Carbonate, Talc, Magnesium Stearate.</p><p>Film coating composition: HPMC 2910/Hypromellose, Lactose monohydrate, Titanium dioxide, Triacetin, FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, FD&amp;C Red #40/Allura red AC</p><p>aluminum lake, FD&amp;C Blue #2/Indigo carmine aluminum lake.</p><p><strong><u>Rosuvastatin Tablets 20 mg:</u></strong></p><p>The active substance is Rosuvastatin Calcium.</p><p>Each film coated tablet contains Rosuvastatin calcium Ph. Eur. equivalent to 20 mg of Rosuvastatin.</p><p>The other ingredients are: Lactose Monohydrate, Cellulose, Microcrystalline, Crospovidone, Hydroxypropyl Cellulose, Sodium Hydrogen Carbonate, Talc, Magnesium Stearate.</p><p>Film coating composition: HPMC 2910/Hypromellose, Lactose monohydrate, Titanium dioxide, Triacetin, FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, FD&amp;C Red #40/Allura red</p><p>AC aluminum lake, FD&amp;C Blue #2/Indigo carmine aluminum lake.</p><p><strong><u>Rosuvastatin Tablets 40 mg:</u></strong></p><p>The active substance is Rosuvastatin Calcium.</p><p>Each film coated tablet contains Rosuvastatin calcium Ph. Eur. equivalent to 40 mg of Rosuvastatin.</p><p>The other ingredients are: Lactose Monohydrate, Cellulose, Microcrystalline, Crospovidone, Hydroxypropyl Cellulose, Sodium Hydrogen Carbonate, Talc, Magnesium Stearate.</p><p>Film coating composition: HPMC 2910/Hypromellose, Lactose monohydrate, Titanium dioxide, Triacetin, FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, FD&amp;C Red #40/Allura red AC aluminum lake, FD&amp;C Blue #2/Indigo carmine aluminum lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Rosuvastatin Tablets looks like? 

Rosuvastatin Tablets 10 mg :

Light pink to pink, round, bevel edged biconvex film coated tablets debossed with 'H' on one side   and 'R4' on the other side.

Rosuvastatin Tablets 20 mg :

Light pink to pink, round, bevel edged biconvex  film coated tablets debossed with 'H' on one side  and 'R5' on the other side.

Rosuvastatin Tablets 40 mg :

Light pink to pink, round, bevel edged biconvex film coated tablets debossed with 'H' on one side and 'R6' on the other side.

How supplied:

Rosuvastatin Tablets are supplied in Blister pack. Rosuvastatin Tablets 10 - Box of 30 blister tablets (3x10’s) Rosuvastatin Tablets 20 - Box of 30 blister tablets (3x10’s) Rosuvastatin Tablets 40 - Box of 30 blister tablets (3x10’s)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>Saudi Amarox Industrial Company Aljameah Street, Malaz quarter,</p><p>Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April, 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي روست أقراص على روزوفاستاتین والتي تنتمي إلى مجموعة العقاقیر التي تسمى الستاتین أو مخفضات الكولیسترول&nbsp;&nbsp; وبالتالي فإن روست یوصف في الحالات التالیة:&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند ارتفاع مستوى الكولیسترول ، الذي قد یؤدي إلى احتمال حدوث النوبة القلبیة أو الجلطة .&nbsp;</p><p dir="RTL">یتم وصف الأدویة الخافضة للكولیسترول بشكل خاص وذلك بعد أن أصبح تغییر النظام الغذائیة وممارسة التمارین الریاضیة غیر كاف لضبط مستویات الكولیسترول ، وعندھا یجب الاستمرار في الأنظمة الغذائیة المخفضة للكولیس ترول وممارسة التمارین الریاضیة بالإضافة إلى تناول</p><p dir="RTL">روست .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال وجود عوامل أخرى تزید من مخاطر حدوث النوبة القلبیة ، أو السكتة الدماغیة أو مشاكل قلبیة أخرى .&nbsp;</p><p>قد تحدث النوبة القلبیة أو أو السكتة الدماغیة أو المشاكل الأخرى نتیجة مرض یسمى تصلب الشریاین ، ویحدث ھذا نتیجة تراكم الرواسب الدھنیة</p><p dir="RTL">في الشرایین .</p><p dir="RTL"><strong>ما ھي أھمیة الاستمرار في تناول روست:&nbsp; </strong></p><p dir="RTL">یستخدم بغرض ظبط مستویات المواد الدھنیة في الدم المسماة بالدھون ، والأكثر شیوعا منھا ھو الكولیسترول .&nbsp;</p><p dir="RTL">ھناك عدة أنواع من الكولیسترول في الدم: الكولیسترول الضار( LDL-C) والكولیسترول الجید( HDL-C)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یمكن لروست تخفیض مستوى الكولیسترول الضار وزیادة مستوى الكولیسترول الجید .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یساھم روست في منع إنتاج الجسم للكولیسترول الضار ، بالإضافة إلى زیادة ودعم قدرة الجسم على إزالته من الدم والتخلص منه.</p><p dir="RTL">وبطبیعة الحال فإن ارتفاع مستوى الكولیسترول لا تصاحبه أي أعراض ظاھرة عند معظم الأشخاص ، إلا أنه في حال إھمال معالجته فمن الممكن أن تتراكم الرواسب الدھنیة على جدران الأوعیة الدمویة مسببة تضیقھا .&nbsp;&nbsp;</p><p>وفي بعض الأحیان فقد یتم انسداد ھذه الأوعیة الدمویة ، الأمر الذي یؤدي لانقطاع الدم وعدم وصوله إلى القلب أو الدماغ وبالتالي حدوث النوبة</p><p>القلبیة أو السكتة الدماغیة . أما إذا تم تصحیح مستویات الكولیسترول فإن ذلك یخفض من مخاطر حدوث النوبة القلبیة أو السكتة الدماغیة أو</p><p dir="RTL">الأعراض والمشاكل ال صحیة المصاحبة لذلك .</p><p dir="RTL">من الضروري <strong>الاستمرار في تناول روست أقراص </strong>، بصرف النظر عن تعدیل مستوى الكولیسترول إلى المستوى الصحیح ، <strong>حیث أنه یمنع ارتفاع مستویات الكولیسترول من جدید .</strong>&nbsp;&nbsp;</p><p dir="RTL">ومع ذلك یجب التوقف عن تناوله في حال طلب الطبیب ذلك أو عند حدوث الحمل بالنسبة للسیدات .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال روست أقراص:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسیة (فرط الحساسیة) تجاه روزوفاستاتین أو أي من مكوناته.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال الحمل أو الرضاعة الطبیعیة ، إذا أصبحت حاملا أثناء تناول روست فیجب التوقف عن تناوله بشكل فوري وإخبار طبیبك ، مع ضرورة تجنب الحمل أثناء تناول روست وذلك باستعمال موانع الحمل الملائمة .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مرض كبدي .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشاكل في الكلى .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وجود آلام عضلیة متكررة أو غیر قابلة للتفسیر .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتم تتناولون عقار سیكلوسبورین (الذي یستخدم على سبیل المثال بعد عملیات زرع الأعضاء) .</p><p dir="RTL">إذا كان أي من المذكور أعلاه ینطبق علیكم (وفي حالة الشك ، یرجى استشارة الطبیب) .&nbsp;</p><p dir="RTL"><strong>وبالإضافة إلى ذلك ، فإنه لا یجب تناول روست </strong><strong>٢٠</strong><strong> ملجم (الجرعة القصوى) في الحالات التالیة:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وجود مشاكل خفیفة في الكلیة( وفي حالة الشك ، یرجى استشارة الطبیب) .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدم أداء الغدة الدرقیة لوظائفھا بالشكل المطلوب .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي من الآلام العضلیة المتكررة أو غیر القابلة للتفسیر ، أو عند وجود حالات سابقة شخصیة أو عائلیة لمشاكل عضلیة ، أو حالات سابقة للمشاكل العضلیة المصاحبة لتناول العقاقیر الأخرى المخفضة للكولیسترول .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول كمیات كبیرة من الكحول بشكل منتظم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من العرق الآسیوي (الیابان ، الصین ، الفیلیبین ، فیتنام ، كوریا أو الھند)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقیر أخرى تسمى الفایبریت المستخدمة لتخفیض مستوى الكولیسترول .</p><p dir="RTL">وفي حال انطبق أي من المذكور أعلاه علیكم( أو في حالة الشك) ، یرجى استشارة الطبیب .&nbsp;</p><p dir="RTL"><strong>التحذیرات والاحتیاطات:&nbsp; </strong></p><p dir="RTL">تحدث إلى طبیبك أو إلى الصیدلي قبل تناول روست .&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong>إذا كنت تعاني من وجود مشاكل في الكلى .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وجود مشاكل في الكبد .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي من الآلام العضلیة المتكررة أو الغیر قابلة للتفسیر ، أو عند وجود حالات سابقة شخصیة أو عائلیة م ن المش اكل العضلیة ، أو حالات سابقة من المشاكل العضلیة المصاحبة لتناول العقاقیر المخفضة للكولیسترول الأخرى ، أخبر طبیبك على الفور في حال عانیتم من أي آلام عضلیة غیر قابلة للتفسیر وبشكل خاص إذا ترافقت مع توعك أو حمى .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول كمیات كبیرة من الكحول بشكل منتظم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدم أداء الغدة الدرقیة لوظائفھا بالشكل المطلوب .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وجود قصور حاد في التنفس .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقیر أخرى تسمى الفایبریت المستخدمة لتخفیض مستوى الكولیسترول ، یجب قراءة ھذه النشرة بدقة بصرف النظر عن تناولكم لعقاقیر لخفض مستوى الكولیسترول مسبقا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول علاج التھاب فیروس لنقص المناعة المكتسبة ، مثل لوبینافیر / ریتونافیر ، یرجى الرجوع إلى فقرة <strong>تناول أدویة أخرى مع روست </strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول المضادات الحیویة التي تحتوي على حمض فوسیدیك ، یرجى الرجوع إلى فقرة <strong>تناول أدویة أخرى مع روست </strong>.</p><p dir="RTL"><strong>الأطفال والمراھقین</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كان سن المریض أقل من عشر سنوات ، یجب عدم تناول روست من قبل الأطفال الأصغر من عشر سنوات .</p><p dir="RTL">في حال كان المریض أقل من ١٨ عام: فإن جرعة روست ٢٠ ملغم أقراص غیر ملائمة للأطفال والمراھقین تحت سن ١٨ عام .</p><p dir="RTL">في حال كان المریض یتجاوز السبعین عام (فعندھا یتم تناوله حسب تقدیر الطبیب للجرعة الأولیة الملائمة من روست أقراص)&nbsp;</p><p dir="RTL">إذا كان المریض من العرق الآسیوي (الیابان ، الصین ، الفیلیبین ، فیتنام ، كوریا أو الھند) فعندھا یختار الطبیب الجرعة الأولیة الملائمة من روست أقراص .</p><p dir="RTL">إذا كان أي من ما سبق ینطبق علیك (أو إذا لم تكن متأكدا):&nbsp;</p><p dir="RTL">فیجب عدم تناول روست ٢٠ ملغم أقراص (الجرعة القصوى) ومراجعة طبیبكم أو الصیدلاني قبل البدء في تناول أي جرعة من روست .&nbsp;</p><p dir="RTL">یمكن أن تؤثر مخفضات الكولیسترول من نوع الستاتین على الكبد وذلك في عدد قلیل من الناس ، ویتم اكتشاف ذلك من خلال اختبار بسیط یوضح ویبین ارتفاع مستویات أنزیمات الكبد في الدم ، ویمكن للطبیب المشرف علیكم القیام بإجراء ھذا الاختبار (اختبار وظائف الكبد) قبل وأثناء العلاج بتناول روست أقراص .&nbsp;</p><p dir="RTL">أثناء فترة العلاج بتناول روست أقراص سوف یقوم الطبیب بفحصك عن كثب إذا كنت مصابا بمرض السكري أو معرض لخطر الإصابة بمرض السكري . من المحتمل أن تكون عرضة لخطر الإصابة بمرض السكري إذا كان لدیك مستویات عالیة من السكریات والدھون في الدم ، الوزن الزائد ، وارتفاع ضغط الدم .&nbsp;</p><p dir="RTL"><strong>تناول أدویة أخرى مع روست:&nbsp;&nbsp; </strong></p><p dir="RTL">أخبر طبیبك أو الصیدلي أو الممرضة إذا كنت تناولت ، أو قد تتناول مؤخرا أي أدویة أخرى وعلى وجه الخصوص أخبر طبیبك إذا كنت تتناول أي من الأدویة التالیة :&nbsp;</p><p dir="RTL">على وجه الخصوص یجب إبلاغ الطبیب في حال تناولكم لأي من العقاقیر التالیة: سیكلوسبورین (یستخدم على سبیل المثال بعد القیام بعملیات زرع الأعضاء) ، الوارفارین أو كلوبیدوجریل (أو أي من العقاقیر الأخرى المستخدمة لسیولة الدم) ، الفایبریت (مثل الج یمفیبروزول ، فینوفیبریت) أو أيمن الأدویة الأخرى المستخدمة لتخفیض مستوى الكولیسترول (مثل إیزیتیمیب) ، علاجات عسر الھضم (المستخدمة لتعدیل مستوى الحمض في المعدة) ، إیرثرومایسین (مضاد حیوي - یرجى الاطلاع على التحذیرات والاحتیاطات) ، وسائل منع الحمل عن طریق الفم (حبوب منع الحمل)&nbsp; ،علاجات الھرمونات التعویضیة أو لوبینافیر / ریتونافیر (یستخدم لمكافحة فیروس نقص المناعة المكتسبة - یرجى الإطلاع على التحذیرات والاحتیاطات) . تأثیر ھذه الأدویة یمكن أن یتغیر مع تناول أقراص روزوفاستاتین ویمكن لھذه الأدویة أن تغیر من تأثیر أقراص روست&nbsp; .&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبیعیة:&nbsp; </strong></p><p dir="RTL">یجب عدم تناول أقراص روست أثناء فترة الحمل أو الرضاعة الطبیعیة . إذا أصبحت حاملا أثناء تناول روست أقراص ، یجب التوقف عن تناولھ على الفور وأخبر طبیبك . یجب على النساء استخدام وسائل منع الحمل المناسبة أثناء العلاج بتناول روست أقراص وذلك لتجنب الحمل .&nbsp;</p><p dir="RTL">اسأل طبیبك أو الصیدلي عن المشورة قبل تناول أي دواء .&nbsp;</p><p dir="RTL"><strong>القیادة واستخدام الآلات&nbsp; </strong></p><p dir="RTL">معظم الناس یمكنھم قیادة السیارة وتشغیل الآلات أثناء العلاج بتناول روست أقراص &ndash; حیث أنه لن یؤثر على قدرتھا. ومع ذلك ، فإن بعض الناس قد یشعرون بالدوار أثناء العلاج بتناول روست أقراص . إذا شعرت بالدوار ، استشر طبیبك قبل محاولة القیادة أو استخدام الآلالت .&nbsp;</p><p dir="RTL"><strong>محتوى روست أقراص من اللاكتوز.&nbsp; </strong></p><p dir="RTL">إذا أخبرك طبیبك من قبل أن لدیك مشكلة تجاه تناول بعض السكریات (اللاكتوز أو سكر الحلیب) ، اتصل بطبیبك قبل تناول روست أقراص .&nbsp;</p><p>للإطلاع على قائمة المكونات كاملة یرجى الاطلاع على فقرة معلومات أخرى .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا ھذا الدواء كما وصف لك الطبیب ، استشر الطبیب أو الصیدلي إن لم تكن متأكدا ً&nbsp; .&nbsp;</p><p dir="RTL">الجرعات المعتادة بالنسبة البالغین&nbsp;</p><p dir="RTL">إذا كنت تتناول روست أقراص لخفض نسبة الكولیسترول ا لعالیة:&nbsp;&nbsp;</p><p dir="RTL"><strong>جرعة البدایة&nbsp; </strong></p><p dir="RTL">جرعة البدایة عبارة عن تناول ١٠ ملغم أو ٢٠ ملغم روست أقراص ، حتى لو كنت قد تناولت جرعة أعلى ومختلفة من مجموعة ستاتین من قبل .</p><p dir="RTL">یعتمد اختیار جرعة البدایة على:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الكولیسترول .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الخطورة من إحتمال إ صابتك بأزمة قلبیة أو السكتة الدماغیة .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك عامل قد یجعلك أكثر حساسیة للآثار الجانبیة المحتملة .&nbsp;</p><p dir="RTL">یرجى مراجعة الطبیب أو الصیدلي بشأن جرعة البدایة التي تناسبك من روست أقراص .&nbsp;</p><p dir="RTL">قد یقرر طبیبك أن یعطیك أقل جرعة( ٥ ملغم) في الحالات التالیة :&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من الأصول الآسیویة (الیابانیة والصینیة والفلبینیة والفیتنامیة والكوریة والھندیة) .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أكثر من ٧٠ سنة من العمر .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل متوسطة في الكلى .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في خطر من الشعور بآلام في العضلات وآلام (اعتلال عضلي) .&nbsp;</p><p dir="RTL"><strong>زیادة الجرعة والجرعة القصوى في الیوم&nbsp; </strong></p><p dir="RTL">قد یقرر طبیبك زیادة جرعتك . حتى تحصل على الجرعة المناسبة لك من روست أقراص . إذا كنت قد بدأت العلاج بجرعة ٥ ملغم ، قد یقررالطبیب مضاعفة ھذه الجرعة إلى ١٠ ملغم ، ثم ٢٠ ملغم إذا لزم الأمر . إذا بدأت في تناول جرعة روست أقراص ١٠ ملغم ، قد یقرر الطبیب مضاعفة ھذه الجرعة إلى ٢٠ ملغم . سوف تكون ھناك فجوة من أربعة أسابیع بین كل تعدیل في الجرعة&nbsp; .&nbsp;</p><p dir="RTL">الجرعة الیومیة القصوى من روست أقراص ھي ٢٠ ملغم . ھذه الجرعة مخصصة فقط للمرضى الذین یعانون من ارتفاع مستویات الكولیسترول في الدم وارتفاع خطر الإصابة بنوبات قلبیة أو السكتة الدماغیة التي لم تنخفض مستویات الكولسترول لدیھم بما فیه الكفایة بعد تناول ٢٠ ملغم&nbsp; .&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول روست أقراص لتقلیل خطر الإصابة بأزمة قلبیة أو السكتة الدماغیة أو المشاكل الصحیة ذات الصلة:&nbsp;&nbsp; </strong></p><p dir="RTL">الجرعة الموصى بھا ھي ٢٠ ملغم یومیا . ومع ذلك ، قد یقرر طبیبك استخدام جرعة أقل إذا كان لدیك أي من العوامل المذكورة أعلاه .&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراھقین الذین تتراوح أعمارھم بین ١٠-١٧ سنة&nbsp; </strong></p><p dir="RTL">جرعة البدایة المعتادة ھي ١٠ ملغم . طبیبك قد یزید الجرعة حتى تحصل على الجرعة المناسبة لك من روست أقراص . الجرعة الیومیة القصوى من روست أقراص ھي ٢٠ ملغم . ویجب تناول الجرعة مرة واحدة في الیوم . لا ینبغي استخدام روست أقراص ٢٠ ملغم من قبل الأطفال&nbsp; .&nbsp;</p><p dir="RTL"><strong>طریقة تناول روست أقراص&nbsp; </strong></p><p dir="RTL">یتم ابتلاع القرص كاملا مع شرب الماء&nbsp; .&nbsp;</p><p dir="RTL"><strong>تناول روست أقراص</strong> <strong>یومیا</strong> . یمكنك أن تتناول روست أقراص في أي وقت من&nbsp; الیوم مع أو بدون الطعام&nbsp; .&nbsp;</p><p dir="RTL">حاول أن تتناول روست أقراص في نفس الوقت من كل یوم لمساعدتك على تذكر موعد الجرعة&nbsp; .&nbsp;</p><p dir="RTL"><strong>الفحص الدوري لمستویات الكولسترول&nbsp; </strong></p><p dir="RTL">ینبغي زیارة الطبیب بشكل منتظم لفحص مستویات الكولسترول ، وللتأكد من أن نسبة الكولیسترول قد وصلت إلى المستوى الصحیح .&nbsp;</p><p dir="RTL">قد یقرر طبیبك زیادة جرعتك بحیث تحصل على الجرعة المناسبة لك من روست أقراص .&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من روست أقراص:</strong>&nbsp;</p><p dir="RTL">یجب الاتصال بطبیبك أو أقرب مستشفى للحصول على استشارة .&nbsp;</p><p dir="RTL">وإذا ذھبت إلى المستشفى أو تلقیت علاجا لحالة طبیة أخرى ، فیجب إبلاغ الطاقم الطبي بأنك تتناول روست أقراص .&nbsp;</p><p dir="RTL"><strong>إذا نسیت تناول روست أقراص:</strong>&nbsp;</p><p dir="RTL">إذا نسیت تناول جرعة فلا داعي للقلق ، تناول الجرعة الاعتیادیة في الیوم التالي كالمعتاد . لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة .&nbsp;</p><p dir="RTL"><strong>التوقفت عن تناول روست أقراص:</strong>&nbsp;</p><p dir="RTL">یجب أن تخبر طبیبك برغبتك في التوقف عن تناول روست أقراص ، فقد یرتفع مستوى الكولیسترول لدیك مجددا في حال توقفك عن تناول روست أقراص .&nbsp;&nbsp;</p><p dir="RTL">إذا كان لدیك أیة أسئلة أخرى حول ھذا المنتج واستخدامه اسأل طبیبك أو الصیدلي .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة ، یمكن أن یتسبب ھذا الدواء&nbsp; في آثار جانبیة ، على الرغم من أنھا لا تؤثر في الجمیع . من المھم إدراك طبیعة التأثیرات الجانبیة ، إذ أنھا تكون عادة طفیفة وتختفي بعد فترة زمنیة قصیرة .&nbsp;</p><p dir="RTL">یجب التوقف عن تناول روست أقراص والحصول على مساعدة طبیة بشكل فوري في حال حدوث أي من ردود الفعل التحسسیة التالیة:&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مع أو بدون تورم الوجه ، الشفتین ، اللسان و / أو الحنجرة&nbsp; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه ، الشفتین ، اللسان و / أو الحلق والذي قد یتسبب في صعوبات في البلع&nbsp; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة جلدیة شدیدة (مع نتوئات منتفخة) .</p><p dir="RTL">وكذلك یجب التوقف عن تناول روست واستشارة طبیبك بشكل فوري في حال عانیت من أي من الآلام العضلیة غیر المعتادة ، والتي تستمر أطول مما ھو متوقع .&nbsp;</p><p dir="RTL">ومن المعروف أن الأعراض العضلیة تكون أكثر شیوعا لدى الأطفال والمراھقین أكثر من البالغین . وكما ھو الحال بالنسبة لعقاقیر الستاتین الأخرى فإن عددا ضئیلا من الناس قد یعانى من تأثیرات وأعراض عضلیة غیر مستحبة ، وفي بعض الحالات النادرة أصبح ھذا التلف العضلي ذو تأثیر خطیر على الحیاة وھو ما یعرف باسم انحلال العضلات الھیكلیـة المخططـة.&nbsp;&nbsp;</p><p dir="RTL"><strong>أعراض جانبیة شائعة (قد تصیب أقل من شخص من أصل ١٠ أشخاص أو شخص من أصل ١٠٠ شخص) .&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمسا ك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثیان &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنھاك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة نسبة بروتین البول &ndash; وتعود تلك النسبة عادة إلى وضعھا الطبیعي دون الحاجة إلى التوقف عن تناول روست (فقط في حال تناول روست أقراص ٤٠ م لغم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري ، وبالأخص لدى المرضى الذین لدیھم نسبة عالیة من السكریات والدھون في الدم ، ویعانون من زیادة الوزن وارتفاع ضغط الدم . سیقوم الطبیب بمراقبتك أثناء تناولك لھذا الدواء&nbsp; .</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض جانبیة غیر شائعة (قد تصیب أقل من شخص من أصل ١٠٠ شخص أو شخص من أصل ١٠٠٠ شخص) .&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ، حكة أو أي من ردود الفعل التحسسیة الأخرى .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة نسبة بروتین البول &ndash; وتعود تلك النسبة عادة إلى وضعھا الطبیعي دون الحاجة إلى إیقاف تناول روست (فقط في حال تناول روست أقراص ١٠ و ٢٠ ملغم) .</p><p dir="RTL"><strong>أعراض جانبیة نادرة (قد تصیب أقل من شخص من أصل ١٠٠٠ شخص أو شخص من أصل ١٠٠٠٠ شخص) .&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شدید &ndash; وتشمل أعراض علي تورم الوجه، الشفتین ، اللسان و / أو الحلق وصعوبة في البلع و التنفس ، حكة جلدیة شدیدة (مع نتوئات منتفخة) . فإذا كنت تعتقد أنك تعاني من رد فعل تحسسي ، یجب التوقف عن تناول روست أقراص والحصول على مساعدة طبیة بشكل فوري&nbsp; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضرر العضلات &ndash; وعندھا وكإجراء وقائي یجب التوقف عن تناول روست واستشارة طبیبك فورا في حال عانیت من آلام عضلیة غیر معتادة لفترة زمنیة أطول من المتوقع .&nbsp; &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في المعدة (التھاب البنكریاس)&nbsp; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة في إنزیمات الكبد في الدم &nbsp;</p><p dir="RTL"><strong>أعراض جانبیة نادرة جدا (قد تصیب أقل من شخص من أصل ١٠٠٠٠) .&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الیرقان (اصفرار الجلد والعینین)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الكبد&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار الدم في البول&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب في الساق والذراعین( التنمیل)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة حجم الثدي في الرجال( تثدي الرجل )</p><p dir="RTL"><strong>أعراض جانبیة أخرى معدلاتھا غیر معلومة:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسھال&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستیفنز جونسون (حالة خطرة في الجلد والفم والعین والأعضاء التناسلیة)&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق في التنفس&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (تورم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم ، بما في ذلك الأرق والكوابیس&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصعوبات الجنسیة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كآبة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل التنفس ، بما في ذلك السعال المستمر و / أو ضیق في التنفس أو الحمى&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الوتر&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات المستمر&nbsp;</p><p dir="RTL">إذا واجھت أي آثار جانبیة ، تحدث مع طبیبك أو الصیدلي . وھذا یشمل أي آثار جانبیة محتملة.&nbsp;&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبیة:&nbsp;&nbsp; </strong></p><p dir="RTL">إذا زادت حدة&nbsp; أي من ھذه الأعراض الجانبیة ، أو لاحظت ظھور أعراض جانبیة غیر ما تم ذكره في ھذه النشرة ، یرجى إبلاغ الطبیب المعالج أو الصیدلي . وھذا یشمل أي آثار جانبیة محتملة غیر مدرجة في ھذه النشرة . یمكنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة (انظر التفاصیل أدناه) .</p><p dir="RTL">بالإبلاغ عن الآثار الجانبیة یمكنك المساعدة في توفیر مزید من المعلومات حول أمان ھذا الدواء .&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب أن یتم حفظ العبوة في درجة حرارة أقل من ٣٠ درجة مئویة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب أن یتم حفظ العبوة بعیدا عن الرطوبة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحفظ بعیدا عن متناول أیدي الأطفال أو على مرأى منھم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم روست أقراص بعد انتھاء تاریخ الصلاحیة المذكور على العبوة الخارجیة . تاریخ انتھاء الصلاحیة یشیر إلى الیوم الأخیر من ذلك الشھر.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ینبغي أن یتم التخلص من الأدویة في میاه الصرف الصحي أو عن طریق النفایات المنزلیة . اسأل الصیدلي عن كیفیة التخلص من الأدوية التي لم تعد مطلوبة . ھذه التدابیر تساعد في الحفاظ على البیئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحویه علبة روست:&nbsp;&nbsp; </strong></p><p dir="RTL"><strong><u>روست أقراص ١٠ ملغم</u></strong><strong> </strong></p><p dir="RTL">المادة الفعالة ھي روزوفاستاتین الكالسیوم .&nbsp;</p><p dir="RTL">یحتوي كل قرص مغطى بطبقة رقیقة على ١٠ ملغم من روزوفاستاتین( على ھیئة روزوفاستاتین الكالسیوم) .&nbsp;</p><p dir="RTL">الصواغات الأخرى ھي: لاكتوز أحادي الھیدرات ، سیللو ز دقیق التبلور، كروس كارملوس الصودیوم ، كروسبوفیدون ، ھیدروكسي بروبیل السلیلوز ،بیكربونات الصودیوم ، التلك ، ستیرات المغنیسیوم .&nbsp;</p><p dir="RTL">طبقة الكسوة الخارجیة: ھیدروكسي بروبیل میثیل السلیلوز٢٩١٠/ ھیبرمیلوز ، لاكتوز أحادي الھیدرات ، ثاني أكسید التیتانیوم ، تریاسیتین ،</p><p>&nbsp; FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, &nbsp;: مكسبات&nbsp; اللون من نوع&nbsp; FD&amp;C Red #40/Allura red AC aluminum lake,</p><p>&nbsp;&nbsp; &nbsp;FD&amp;C Blue #2/Indigo carmine aluminum lake</p><p dir="RTL"><strong><u>روست أقراص ٢٠ ملغم</u></strong><strong> </strong></p><p dir="RTL">المادة الفعالة ھي روزوفاستاتین الكالسیوم.&nbsp;</p><p dir="RTL">یحتوي كل قرص مغطى بطبقة رقیقة على ٢٠ ملغم من روزوفاستاتین( على ھیئة روزوفاستاتین الكالسیوم) .&nbsp;</p><p dir="RTL">الصواغات الأخرى ھي: لاكتوز أحادي الھیدرات ، سیللو ز دقیق التبلور، كروس كارملوس الصودیوم، &nbsp;كروسبوفیدون ، ھیدروكسي بروبیل السلیلوز، بیكربونات الصودیوم ، التلك ، ستیرات المغنیسیوم .&nbsp;</p><p dir="RTL">طبقة الكسوة الخارجیة: ھیدروكسي بروبیل میثیل السلیلوز٢٩١٠/ ھیبرمیلوز ، لاكتوز أحادي الھیدرات ، ثاني أكسید التیتانیوم ، تریاسیتین ،</p><p>&nbsp; FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, &nbsp;: مكسبات&nbsp; اللون من نوع&nbsp; FD&amp;C Red #40/Allura red AC aluminum lake,</p><p>&nbsp; FD&amp;C Blue #2/Indigo carmine aluminum lake</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>روست أقراص ١٠ ملغم</u></strong><strong> </strong></p><p dir="RTL">أقراص مغطاه بطبقة رقیقة دائریة محدبة الوجھین مشطوفة الحواف ذات اللون الورد ي إلى الوردي الفاتح محفور علیھا &quot; H&quot; من جانب واحد و&quot; R4&quot; من الجانب الآخر.&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong><u>روست أقراص ٢٠ ملغم</u></strong><strong> </strong></p><p dir="RTL">أقراص مغطاه بطبقة رقیقة دائریة محدبة الوجھین مشطوفة الحواف ذات اللون الوردي إلى الوردي الفاتح محفور علیھا &quot; H&quot; من جانب واحد و &quot;R5&quot; من الجانب الآخر.&nbsp;&nbsp;</p><p dir="RTL"><strong>توافر روست أقراص بالسوق&nbsp; </strong></p><p dir="RTL">یتوافر روست أقراص على شكل علبة&nbsp;&nbsp;</p><p dir="RTL">روست أقراص ١٠ ملغم &ndash; علبة تحتوي على ثلاثین قرص عبارة عن ثلاثة شرائط تحتوي على ١٠ أقراص&nbsp; روست أقراص ٢٠ ملغم &ndash; علبة تحتوي على ثلاثین قرص عبارة عن ثلاثة شرائط تحتوي على ١٠ أقراص&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع:&nbsp; </strong></p><p dir="RTL"><strong>شركة هیترو الوحدة رقم </strong><strong>V</strong><strong>&nbsp; </strong></p><p dir="RTL"><strong>حیدر اباد &ndash; تیلانقا &ndash; الهند&nbsp; </strong></p><p dir="RTL">هاتف : ٠٠٩١٨٤٥٨٢٧٥٣١٤&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب حق التسویق: </strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong><br />شارع الجامعة &ndash; الملز - الریاض المملكة العربیة السعودیة .&nbsp;&nbsp;&nbsp;&nbsp;</p><p>هاتف : ٠٠٩٦٦١١٤٧٧٢٢١٥&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مایو/  ٢٠١٨ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rost (Rosuvastatin) tablets 10mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin Tablets 10mg: 
Each Film-Coated tablet contains 10 mg of Rosuvastatin (as Rosuvastatin Calcium). 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin Tablets 10mg 
Light pink to pink, round, bevel edged biconvex film coated tablets debossed with 'H' on one side and 'R4' on the other side.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolaemia</strong></p><p>Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p><strong>Prevention of Cardiovascular Events</strong></p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.<strong> </strong></p><p>Rosuvastatin tablets may be given at any time of day, with or without food.</p><p><strong>Treatment of hypercholesterolaemia</strong></p><p>The recommended start dose is 5 or 10 mg orally once daily in both&nbsp; statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions. A dose adjustment to the next dose level can be made after 4 weeks, if necessary. In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses, a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed. Specialist supervision is recommended when the 40 mg dose is initiated.</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily.</p><p><strong>Paediatric population</strong></p><p>Paediatric use should only be carried out by specialists.</p><p><u>Children and adolescents 10 to 17 years of age (boys Tanner Stage II and above, and girls who are at least 1 year post-menarche)</u></p><p>In children 6 to 9 years&nbsp;&nbsp; with heterozygous familial hypercholesterolaemia the usual&nbsp; dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10mg have not been studied in this population.</p><p>In Children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usaual dose range is 5-20mg orally once daily. Safety and efficacy of doses greater than 20mg have not been studied in this population.</p><p>Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations. Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.&nbsp;</p><p><u>Homozygous familial hypercholesterolaemia</u></p><p>In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.</p><p>A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations . Children and adolescents should be placed on standard cholesterollowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p>There is limited experience with doses other than 20 mg in this population.</p><p>The 40 mg tablet is not suitable for use in paediatric patients.</p><p><u>Children younger than 6 years</u></p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, rosuvastatin is not recommended for use in children younger than 6 years.</p><p><strong>Use in the elderly</strong></p><p>A start dose of 5 mg is recommended in patients &gt;70 years. No other dose adjustment is necessary in relation to age.&nbsp;</p><p><strong>Dosage in patients with renal insufficiency</strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance of &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment.</p><p>The use of rosuvastatin in patients with severe renal impairment is contraindicated for all doses.&nbsp;</p><p><strong>Dosage in patients with hepatic impairment</strong></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child Pugh scores of 8 and 9. In these patients an assessment of renal function should be considered. There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease.&nbsp;</p><p><strong>Race</strong></p><p>Increased systemic exposure has been seen in Asian subjects. The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p><strong>Genetic polymorphisms</strong></p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure. For patients who are known to have such specific types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p><strong>Dosage in patients with pre-disposing factors to myopathy</strong></p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy.</p><p>The 40 mg dose is contraindicated in some of these patients.</p><p><strong>Concomitant therapy</strong></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir; Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing rosuvastatin therapy. In situations where co-administration of these medicinal products with rosuvastatin is unavoidable, the benefit and the risk of concurrent treatment and rosuvastatin dosing adjustments should be carefully considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin  is contraindicated: 
-	In   patients with hypersensitivity to rosuvastatin or to any of the excipients. 
-	In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN). 
-	In   patients with severe renal impairment (creatinine clearance <30 ml/min). 
-	In   patients with myopathy. 
-	In   patients receiving concomitant ciclosporin. 
-	during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures. 
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/ rhabdomyolysis. Such factors include: 
− Moderate renal impairment (creatinine clearance < 60 ml/min) 
− Hypothyroidism  
− Personal or family history of hereditary muscular disorders 
− Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate − Alcohol abuse 
− Situations where an increase in plasma levels may occur  
− Asian patients 
− Concomitant use of fibrates. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renal Effects</p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease. The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p>Skeletal Muscle Effects</p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in&nbsp; rosuvastatin&nbsp; -treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded and caution should be exercised with their combined use.&nbsp;</p><p>As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin&nbsp; in post-marketing use is higher at the 40 mg dose.&nbsp;</p><p>Creatine Kinase Measurement</p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.&nbsp;</p><p>Before Treatment</p><p>Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p>&bull;&nbsp; renal impairment&nbsp;</p><p>&bull;&nbsp; hypothyroidism&nbsp;</p><p>&bull;&nbsp; personal or family history of hereditary muscular disorders</p><p>&bull;&nbsp; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p>&bull;&nbsp; alcohol abuse</p><p>&bull;&nbsp; age &gt;70 years</p><p>&bull;&nbsp; situations where an increase in plasma levels may occur.</p><p>&bull;&nbsp; concomitant use of fibrates.</p><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.&nbsp;</p><p>Whilst on Treatment</p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>In clinical trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate.</p><p>Rosuvastatin Tablets must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic&nbsp; acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of Rosuvastatin Tablets and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>Rosuvastatin Tablets&nbsp; should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures). <u>&nbsp;Liver Effects</u></p><p>As with other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin Tablets should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in postmarketing use is higher at the 40 mg dose.&nbsp;</p><p>In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Rosuvastatin Tablets.</p><p>Race</p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians.</p><p>Protease inhibitors</p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Rosuvastatin Tablets in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Rosuvastatin Tablets doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of Rosuvastatin Tablets is adjusted.</p><p>Lactose intolerance</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or 66+glucose-galactose malabsorption should not take this medicine.</p><p>Interstitial lung disease</p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy. Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>Diabetes Mellitus</p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p><strong><u>Paediatric population</u> </strong></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected.&nbsp;</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of co-administered medicinal products on rosuvastatin</u></p><p><strong>Transporter protein inhibitors:</strong> Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy.&nbsp;</p><p><strong>Ciclosporin:</strong> During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). rosuvastatin is contraindicated in patients receiving concomitant ciclosporin. Concomitant administration did not affect plasma concentrations of ciclosporin.&nbsp;</p><p><strong>Protease inhibitors</strong>: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub> respectively. The concomitant use of rosuvastatin and some protease inhibitor combinations may be considered after careful consideration of rosuvastatin dose adjustments based on the expected increase in rosuvastatin exposure.</p><p><strong>Gemfibrozil and other lipid-lowering products</strong>: Concomitant use of rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin C <sub>max</sub> and AUC.</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate. These patients should also start with the 5 mg dose.</p><p><strong>Ezetimibe: </strong>Concomitant use of 10 mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2 fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between rosuvastatin and ezetimibe cannot be ruled out.</p><p><strong>Antacid</strong>: The simultaneous dosing of rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.</p><p><strong>Erythromycin:</strong> Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub> of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p><strong>Cytochrome P450 enzymes:</strong> Results from <em>in vitro</em> and <em>in vivo</em> studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).&nbsp;</p><p><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</strong> When it is necessary to co-administer rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of rosuvastatin should be adjusted. Start with a 5 mg once daily dose of rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of rosuvastatin should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of rosuvastatin taken without interacting medicinal products, for example a 20 mg dose of rosuvastatin with gemfibrozil (1.9fold increase), and a 10 mg dose of rosuvastatin with combination ritonavir/atazanavir (3.1-fold increase).</p><table border="0" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin </strong></p><p><strong>AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months&nbsp;</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir 150mg OD , 7 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.8- fold &uarr;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days&nbsp;</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours&nbsp;</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID&nbsp;</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p><sup>**</sup>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p><sup>**</sup>1.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg/ritonavir 100 mg BID,</p><p>8 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Aleglitazar 0.3 mg, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>40 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Silymarin 140 mg TID, 5 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 67 mg TID, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>10 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin 450 mg OD, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole 200 mg BID, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole 200 mg OD, 11 days&nbsp;</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days&nbsp;</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days&nbsp;</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone.</p><p>Data given as % change represent % difference relative to rosuvastatin alone.&nbsp;</p><p>Increase is indicated as &ldquo;&uarr;&ldquo;, no change as <strong>&ldquo;</strong>&harr;&rdquo;, decrease as &ldquo;&darr;&rdquo;.&nbsp;</p><p><sup>**</sup>Several interaction studies have been performed at different rosuvastatin dosages, the table shows the most significant ratio&nbsp;</p></td></tr></tbody></table><p>OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily&nbsp;</p><p>Effect of rosuvastatin on co-administered medicinal products</p><p><strong>Vitamin K antagonists: </strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p><strong>Oral contraceptive/hormone replacement therapy (HRT): </strong>Concomitant use of rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant rosuvastatin and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p><strong>Other medicinal products:</strong></p><p><strong>Digoxin:</strong> Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.&nbsp;</p><p><strong>Fusidic Acid:</strong> Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination. If treatment with systemic fusidic acid Rosuvastatin Tablets treatment should be discontinued throughout the duration of the fusidic acid treatment<sub>.</sub>&nbsp;</p><p><strong>Paediatric population: </strong>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>rosuvastatin&nbsp; is contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures.&nbsp;</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity. If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.&nbsp;</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of rosuvastatin on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, rosuvastatin is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of rosuvastatin -treated patients were withdrawn due to adverse reactions.</p><p>Tabulated list of adverse reactions</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</p><table border="0" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ </strong></p><p><strong>class</strong></p></td><td style="vertical-align:bottom"><p><strong>Common</strong></p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Uncommon</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:bottom"><p><strong>Very rare</strong></p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Not known</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>lymphatic system disorders&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune &nbsp;&nbsp;&nbsp;&nbsp; system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Diabetes mellit &nbsp; us<sup>1</sup></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous &nbsp;&nbsp;&nbsp;&nbsp; system</p><p>disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;Headache&nbsp; Dizziness&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Polyneuropathy</p><p>Memory loss&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough&nbsp;</p><p>Dyspnoea&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top"><p>Constipation&nbsp; Nausea&nbsp; Abdominal pa in&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Diarrhoea&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;Jaundice&nbsp; Hepa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; titis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritis&nbsp;</p><p>Rash&nbsp;</p><p>Ur ticaria&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculo-skeletal and &nbsp;&nbsp;&nbsp;&nbsp; connective</p><p>tissue disorders&nbsp;</p></td><td style="vertical-align:bottom"><p>Myalgia&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Myopathy (including</p><p>myositis)&nbsp;</p><p>Rhabdomyolysis&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia&nbsp;</p></td><td style="vertical-align:top"><p>Tendon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders, sometimes</p><p>complicated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by</p><p>rupture&nbsp;</p><p>Immune-mediated necrotising myopathy&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Gynaecomastia&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;Asthenia&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1 </sup>Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.&nbsp;</p><p><strong>Renal effects: </strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with rosuvastatin and clinical trial data show that the occurrence is low.</p><p><strong>Skeletal muscle effects: </strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg.&nbsp;</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued.</p><p><strong>Liver effects: </strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins:</p><p>Sexual dysfunction.</p><p>Exceptional cases of interstitial lung disease, especially with long term therapy.</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population:</strong> Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults. In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p>Reporting of suspected adverse reactions&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:496px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>&nbsp;o Other GCC States: </em></strong></p><p>&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.<strong> </strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>HMG-CoA reductase inhibitors</p><p><strong>ATC code: </strong>C10A A07&nbsp;</p><p>Mechanism of action</p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p>Pharmacodynamic effects</p><p>Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I</p><p>(see Table 3). Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C and nonHDLC/HDL-C and the ApoB/ApoA-I ratios.</p><p>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</p><table border="0" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td colspan="2" style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td colspan="2" style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td colspan="2" style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p>Clinical efficacy and safety</p><p>Rosuvastatin is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as diabetics, or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, Rosuvastatin has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. 33% of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/l).&nbsp;</p><p>In a force-titration, open label trial, 42 patients with homozygous familial hypercholesterolaemia were evaluated for their response to Rosuvastatin 20 - 40 mg. In the overall population, the mean LDL-C reduction was 22%.&nbsp;</p><p>In clinical studies with a limited number of patients, Rosuvastatin has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin.</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of rosuvastatin 40mg. The 40mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk. In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.&nbsp;</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patientyears. Total mortality was unchanged in this high risk group (p=0.076).</p><p>In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin,</p><p>6.6% placebo).</p><p>Paediatric population</p><p>In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at least 1 year postmenarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected. This trial (n=176) was not suited for comparison of rare adverse drug events. Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL), and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively. Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non HDL C/HDL-C, ApoB,</p><p>ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years. No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4). Rosuvastatin was studied in a randomised, doubleblind, placebo-controlled, multicenter,&nbsp; cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study. A statistically significant (p=0.005) reduction in LDLC (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), nonHDL-C (22.9%, p=0.003), and ApoB (17.1%, p=0.024) were observed.</p><p>Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, nonHDL-C/HDL-C, and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy. In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%),</p><p>Total-C (19.2%), and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia. The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong> Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p><strong>Distribution</strong>: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><strong>Metabolism:</strong> Rosuvastatin undergoes limited metabolism (approximately 10%). <em>In vitro</em> metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><strong>Excretion:</strong> Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p><strong>Linearity:</strong> Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p><strong>Special populations:</strong></p><p><strong>Age and sex: </strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolaemia was similar to that of adult volunteers (see &ldquo;Paediatric population&rdquo; below).</p><p><strong>Race:</strong> Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub> in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.&nbsp;</p><p><strong>Renal insufficiency:</strong> In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the Ndesmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.<br /><strong>Hepatic insufficiency:</strong> In a study with subjects with varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p><strong>Genetic polymorphisms:</strong> Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p><strong>Paediatric population:</strong> Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patientswith heterozygous familial hypercholesterolaemia 10-17 or 6-17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Rosuvastatin Tablets&nbsp; 10mg:</u> </strong></p><p>The other ingredients are: Lactose Monohydrate, Cellulose, Microcrystalline, Crospovidone, Hydroxypropyl Cellulose, Sodium Hydrogen Carbonate, Talc, Magnesium Stearate.</p><p>Film coating composition: HPMC 2910/Hypromellose, Lactose monohydrate, Titanium dioxide, Triacetin, FD&amp;C Yellow #6/sunset yellow FCF aluminum lake, FD&amp;C Red #40/Allura red AC aluminum lake, FD&amp;C Blue #2/Indigo carmine aluminum lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 X 10s&nbsp; Alu-Alu-blister packs&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Co, Ltd. 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Limited Unit V, Hyderabad, India  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>